Max Healthcare posts Q2 FY25 consolidated PAT at Rs. 281.81 Cr

Max Healthcare Institute has reported total income of Rs. 1,748.30 crores during the period ended September 30, 2024

Apollo Hospitals reports Q2 FY25 consolidated PAT at Rs. 378.8 Cr

Apollo Hospitals Enterprise has reported total income of Rs. 5,627.5 crores during the period ended September 30, 2024

Alembic Pharmaceuticals Q2 FY25 PAT up 12% to Rs. 153 Cr

US Generics grew 5% to Rs. 467 Crores for the quarter

Vijaya Diagnostic Centre posts Q2 FY25 PAT at Rs. 41.95 Cr

Revenue growth was fueled by higher volumes and contributions from both existing and new centres

RPG Life Sciences posts Q2 FY25 revenue Up by 12% YoY

Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25

Kwality Pharma received approval for Leuprorelin Acetate for injectable suspension from Greece

Ichnos Glenmark Innovation to present Phase 1 study of Trispecific ISB 2001 in r/rMM at ASH Annual Meeting

ISB 2001 demonstrated a favorable safety and tolerability profile, and an overall response rate (ORR) of 75% in r/r MM

Mankind Pharma posts Q2 FY25 PAT up 30% at Rs. 659 Cr

Revenue from Operations during Q2 FY25 was Rs. 3,077 crore as compared to Rs. 2,708 crore in Q2 FY24.

Venus Remedies gets approval from Malaysian PIC/S GMP for pre-filled syringe facility

The recognition from Malaysia's NPRA, a member of PIC/S, opens doors to new global business opportunities

Dr. Reddy's Laboratories posts Q2 FY25 PAT at Rs. 1,255.3 Cr

Dr. Reddy's Laboratories has reported total income of Rs. 8,016.2 crores during the period ended September 30, 2024